These in vivo results along with in vitro results validate our mechanistic findings and demonstrate that anlotinib combined with KRAS-G12Ci effectively overcomes resistance through modulation of the c-Myc/ORC2 axis, resulting in significant tumor suppression (Fig. 6M). The gene discussed is KRAS; the disease is neoplasm.